Shamburg News · 8-K filed Oct 14, 2026, 8:30 AM EDT

Coya Therapeutics to Open-Label Extension of ALSTARS Trial for COYA 302 in ALS

COYA · Coya Therapeutics, Inc.

  • Other event
  • Materiality: medium

Coya Therapeutics announced on October 14, 2026 plans to initiate an open-label extension of the Phase 2/3 ALSTARS Trial evaluating COYA 302 in amyotrophic lateral sclerosis, in response to investigator and participant requests. The extension is expected to begin in November 2026 as the first cohort completes the 48-week treatment period. The company also expects the Phase 2 trial of COYA 302 in frontotemporal dementia, previously anticipated in the second half of 2026, to begin in 2027, and states its cash runway guidance is unchanged, with cash expected to fund operations into the second half of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-421066.

Written from the filing by Shamburg Markets. Figures are as reported by the company.